It has been previously reported that FOXP3 expression levels are reduced in Tregs from APS-1 patients compared to healthy controls (16, 17), however we did not find a significant difference in FOXP3 expression between patients and controls in this study. This evidence concerns the gene FOXP3 and autoimmune polyendocrine syndrome type 1.